Introduction
Chronic kidney disease (CKD) is defined as the progressive and irreversible loss of kidney function (glomerular, tubular and endocrine). In its most advanced stage (called endstage chronic renal failure -CRF), the kidneys can no longer maintain the normal internal environment of the patient, requiring the institution of renal replacement therapy 1 .
Peritoneal dialysis (PD) has become popular after the introduction of continuous ambulatory peritoneal dialysis (CAPD).
The CAPD is done at home, cause a smaller impact on the social life of patients, providing a survival equivalent to that offered by hemodialysis 2 , but the occurrence of peritonitis and peritoneal fibrosis, which may progress to encapsulating peritonitis, still limit
CAPD.
An Australian study showed that the risk of developing encapsulating peritonitis is increasing as the patient stay in PD, reaching a prevalence of 19.4% in patients treated for more than eight years 3 . A Scottish study, also showed that the incidence of encapsulating peritonitis increases with time on PD 4 .
Peritoneal fibrosis, which occurs in PD patients, has a complex pathophysiology, with several factors that lead to this situation, including uremia itself, the episodes of peritonitis, and PD solution.
Given the importance of the issue, were developed experimental models to study the mechanism of fibrosis, changes in the intensity by using drug. Ishii et al. 5 developed a model in mice using intraperitoneal injection of chlorhexidine gluconate 0.1% and 15% ethanol dissolved in saline at a dose of 0.3 ml daily, using buffered saline in the control group. The animals were followed for 56 days. All animals in the group that used chlorhexidine and alcohol 18 developed encapsulating peritonitis 5 .
However these models, although induce inflammation and fibrosis,
differ substantially from what happens to patients.
Bui et al. 6 used the infusion of hypertonic PD solution to study the capacity of N-acetylcysteine protect the peritoneum from the harmful action of PD solution. They concluded that the use of PD solution with 3.86% glucose induces significant changes in the peritoneum, and that the use of N-acetylcysteine had a protective effect.
Statins can be used to modify the course of various diseases due to their anti-inflammatory properties, but there are few data regarding its use in preventing peritoneal fibrosis.
Methods
The experiment carried out was submitted to the Ethics 
Results
Five animals died during the follow-up. At the end of the experiment, the sample was: control group 21 days -three animals, control group 49 days -five animals, experimental group 21 days -four animals, experimental group 49 days -three animals.
No other major complications occurred. During the experimental period the animals gained weight, and there was no statistically significant differences between control and experimental groups.
There was thickening of peritoneum parietal, as demonstrated in Table 1 . It was realized that the thickening was even bigger when you complete the period of 49 days. The difference of thickness of peritoneum between the control group and the experiment was greater than in 21 days, although without achieving statistical significance (p=0.229) ( Table 2) . Compared the thicknesses between groups 21 and 49 days, one realizes that there was an intensification of thickening of peritoneum parietal, although without showing significant difference (Table 3) . In visceral peritoneum there was thickening also, although in much less degree than the parietal peritoneum. At 21 days the intensity of the fibrosis was greater in animals of the experiment, although without difference statistically significant (Table 4) . In animals followed by 49 days, the thickness of the visceral peritoneum was greater in the control group, but without reaching statistical significance (Table 5) . Comparing the thickness of the peritoneum at 21 and 49 days, we realized that there was progressive increasing, but without achieving significant statistically difference (Table 6 ). The results of the count of the number of cells in the visceral peritoneum, 21 and 49 days, are shown in Tables 9 and   10 . The number of cells is greater in the experimental group at 21
days, but without statistical significance. The analysis of the degree of fibrosis and the quantity of collagen type I in the abdominal wall at 21 and 49 days, are shown in Tables 11 and 12 . The amount of collagen type I in the parietal peritoneum is much lower in the experimental group at 21 days, but without statistically significant difference. The quantities of collagen type I in the visceral peritoneum at 21 and 49 days are shown in Tables 13 and 14 . In the photos above, points out the increased thickness of the parietal and visceral peritoneum, and realizes with sharpening the presence of blood vessels in the parietal serous. In relation to the number of cells, we have not had any differences between the groups, although the trend has been in the experimental group, with a smaller number of them, at least in the parietal peritoneum. With respect to the amount of collagen, there is no statistically significant differences between the groups, although it was smaller in the parietal peritoneum of the experimental group. There was an increase of collagen, type III in visceral peritoneum to 49 days. This finding should be object of future research. The lack of statistical significance in the findings should not be from the dose of simvastatin administered, because it is similar with used in others experiments [12] [13] .
We had significant mortality during the conduct of the study, although only an animal has died by technical problems, in the case, trauma caused by the metal used to force-feeding.
The others were the death because, apparently unrelated to the experiment. Deaths cannot be attributed to the use of simvastatin.
The high mortality decreased the size of the sample, which may have contributed to not find statistical significance in the analyses made. As the number of the sample was small, there was the impossibility of a proper statistical analysis. More studies with larger sample will be necessary to answer the question.
Conclusion
The use of simvastatin hasn't changed the intensity of fibrosis.
